Michael Goettler is the Group President of Pfizer’s Upjohn business and is a member of the Company’s Executive Leadership Team. Previously, Michael was the Global President, Rare Diseases for Pfizer’s Global Innovative Pharma Business. Michael joined Pfizer through the Wyeth acquisition and was appointed as Regional President, Asia-Pacific for Specialty Care and has held a number of leadership roles across the company including, Global Commercial Officer, Senior Vice President, PIH, and Regional President, Europe for Specialty Care. Michael is a member of the board of directors of PSI (Population Services International), a global health organization dedicated to improving the health of people in the developing world by focusing on serious global health challenges like family planning, HIV and AIDS, and the greatest threats to children under five, including malaria, diarrhea, pneumonia and malnutrition. Michael, a native German, studied in Germany, France and the US. He holds an M.B.A. from the University of Texas at Austin and graduated from the Koblenz School of Corporate Management in Germany, both with summa cum laude. Prior to joining Pfizer, Michael worked at Hoechst, Aventis Pharma, and Sanofi.